Joint meeting ADWP & SAAWP November 2016, Paris, France

Size: px
Start display at page:

Download "Joint meeting ADWP & SAAWP November 2016, Paris, France"

Transcription

1 ,

2 Preliminary Programme 09 November - ADWP Educational 10:00-10:30 Welcome & coffee 1 st session Connective tissue diseases Chair: David Kiely & Renate Arnold 10:30-10:50 How do we make HSCT for SSc safer? EBMT Guidelines Dominique Farge 10:50-11:10 Immune reconstitution and mechanistic aspects Maria-Carolina Oliveira 11:10-11:30 Gene and cell therapies for systemic autoimmune diseases Attilio Bondanza 11:30-11:50 Future protocols and trials in SSc and SLE. Tobias Alexander 2 nd session Crohn s session Chair: John Snowden & Elena Ricart 11:50-12:10 CD guidelines/current recommendations Montserrat Rovira 12:10-12:30 Immune reconstitution in Crohn s disease TBA 12:30-12:50 What comes after ASTIC/ what next trial TBA 12:50-13:00 EBMT data on Crohn s disease Cristina Castilla Llorante Charlotte Brieley 13:00-14:00 Lunch

3 3 rd session Neurological diseases Chair: Paolo Muraro & Hans Hagglund 14:00-14:20 Choice of patient in MS Basil Sharrack 14:20-14:40 Choice of conditioning regimen in MS Riccardo Saccardi 14:40-15:00 Chronic inflammatory demyelinating polyneuropathy (CIDP) Joachim Burman 15:00-15:30 Canadian experience for ASCT in Multiple Sclerosis, Myasthenia Gravis, and Stiff Person Syndrome Harold Atkins 15:30-16:00 Coffee break 4 th session Rare indications Chair: Tobias Alexander & Majid Kazmi 16:00-16:20 Vasculitis and Polymyositis/Dermatomyositis Thomas Daikeler 16:20-16:40 HSCT and Cellular Therapy in immune cytopenia Nicola Cooper 16:40-17:00 HSCT for autoinflammatory paediatric diseases Mario Abinun 17:00-17:20 Close and Discussion

4 10 November - Business meetings 08:30-10:30 Business meetings 10:30-10:45 Coffee break 10:45-12:30 Joint Educational session 5 th session Conditioning regimens and post-transplant care Chair: John Snowden & Regis Peffault de Latour 10:45-11:05 New conditioning regimens what can the ADWP and the SAAWP learn from each other? Jakob Passweg 11:05-11:25 Vaccinations in aplastic anaemia and autoimmune diseases Per Ljungman 11:25-11:35 Secondary autoimmune diseases following HSCT Paul Miller 6 th session ATG Chair: Carlo Dufour & Tobias Alexander 11:35-11:55 Mechanism of Action Phillip Scheinberg 11:55-12:15 Role of ATG in RIC Fabio Ciceri 12:15-12:35 Overlap Syndromes Maurizio Miano 12:45-14:00 Lunch

5 10 November - SAAWP Educational 14:00-14:15 Opening Carlo Dufour, Regis Peffault de Latour 7 th session Chair: Carlo Dufour, Regis Peffault de Latour 14:15-14:45 Physiopathology of idiopathic aplastic anemia Shahram Kordasti 14:45-15:00 Questions Controversy I: Do I consider somatic mutations in AA as MDS? Chair: Shahram Kordasti 15:00-15:15 Yes Austin Kulasekararaj 15:15-15:30 No Gérard Socié 15:30-16:00 Debate 16:00-16:30 Coffee break 8 th session Chair: Gérard Socié 16:30-17:00 First line treatment Judith Marsh 17:00-17:15 Questions

6 Controversy II: Do I offer transplantation for young patients (<20 years) with classic PNH and a matched available sibling donor? Chair: Antonio Risitano 17:15-17:30 Yes Hubert Schrezenmeier 17:30-17:45 No Regis Peffault de Latour 17:45-18:15 Debate 19:30-23:00 Social Event 11 November - SAAWP Educational 9 th session Chair: Marc Bierings 08:00-08:30 MUD transplant for AA. Where we come from, where we are, where we go Jakob Passweg 08:30-08:45 Questions Controversy III: Do I offer upfront MUD in children with aplastic anemia? Chair: Judith Marsh 08:45-09:00 Yes Carlo Dufour 09:00-09:15 No Philip Scheinberg 09:15-09:45 Debate 09:45-10:15 Coffee break

7 10 th session Chair: Mahmoud Aljurf 10:15-10:45 Refractory AA patients: place and management of Eltrombopag Antonio Risitano 10:45-11:00 Questions Controversy IV: What is the best salvage transplantation approach for refractory AA? Chair: Andre Tichelli 11:00-11:15 CBT Regis Peffault de Latour 11:15-11:30 Haplo Jakob Passweg 11:30-12:00 Debate 12:00-13:00 Lunch 11 th session Chair: Andre Tichelli 13:00-13:30 Telomere disease Rodrigo Calado 13:30-13:45 Questions Controversy V: Transplant for telomeropathy? Chair: Alicia Rovo 13:45-14:00 Yes Jean Hugues Dalle 14:00-14:15 No Danielle Townsley 14:15-14:45 Debate 14:45-15:15 Coffee break

8 12 th session Chair: Francesca Fioredda & Jean Soulier 15:15-15:45 Clonal evolution in FA patients: all go to transplantation? Jean Soulier 15:45-16:00 Questions 16:00-16:30 Severe congenital neutropenia: anything new? Francesca Fioredda 16:30-16:45 Questions 16:45-17:15 Closing Remarks

Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples

Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples 4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone

More information

Latest results of sibling HSCT in acquired AA. Jakob R Passweg

Latest results of sibling HSCT in acquired AA. Jakob R Passweg Latest results of sibling HSCT in acquired AA Jakob R Passweg Impact on Outcome: Patient Age, Disease Severity Title: Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and

More information

EBMT ADWP/IEWP. 3 rd 5 th November 2017 Newcastle, UK IEWP Chairman: A Lankester IEWP Secretary: M Albert. Local Chair: A Gennery

EBMT ADWP/IEWP. 3 rd 5 th November 2017 Newcastle, UK IEWP Chairman: A Lankester IEWP Secretary: M Albert. Local Chair: A Gennery EBMT ADWP/IEWP 3 rd 5 th November 2017 Newcastle, UK IEWP Chairman: A Lankester IEWP Secretary: M Albert ADWP Chairman: J Snowden ADWP Secretary: T Alexander Local Chair: A Gennery Telephone: +44 (0)191

More information

OUTCOME AFTER IMMUNOSUPPRESSION

OUTCOME AFTER IMMUNOSUPPRESSION OUTCOME AFTER IMMUNOSUPPRESSION EBMT Aplastic Anemia Educational Meeting Budapest November 1 st 2012 Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplant Unit Hematology, DBBM Federico II University

More information

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British

More information

Severe Aplastic Anemia in Children and Adolescents. Brigitte Strahm 21. April 2018

Severe Aplastic Anemia in Children and Adolescents. Brigitte Strahm 21. April 2018 Severe Aplastic Anemia in Children and Adolescents Brigitte Strahm 21. April 2018 Acquired Aplastic Anemia in children What is aquired aplastic anemia? Camitta, Blood 1976 How A.L.G. acts is unknown, but

More information

Disclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017

Disclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017 2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:

More information

Increase the level of science across the organization with a view to advancing clinical practice;

Increase the level of science across the organization with a view to advancing clinical practice; Annual Report Annual Report Table of Contents Introduction to the EBMT 4 2012 EBMT at a glance 5 Foreword by the EBMT President 6 Highlights of 2013 Strategic Plan by the EBMT Executive Director 7 Feature

More information

AAMDSIF. Aplastic Anemia Research Summary from the DIAGNOSIS RTEL1 Mutations and Bone Marrow Failure

AAMDSIF. Aplastic Anemia Research Summary from the DIAGNOSIS RTEL1 Mutations and Bone Marrow Failure AAMDSIF Aplastic Anemia Research Summary from the 2016 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING A Summary of Selected Scientific Abstracts for Patients with Aplastic Anemia and Their Caregivers DIAGNOSIS

More information

Aplastic Anaemia Genomics: Current data and interpretation

Aplastic Anaemia Genomics: Current data and interpretation An Academic Health Sciences Centre at the heart of a world city... Aplastic Anaemia Genomics: Current data and interpretation Austin G Kulasekararaj Consultant Haematologist King s College Hospital, London

More information

Unrelated allogeneic transplantation for severe aplastic anemia is a treatment

Unrelated allogeneic transplantation for severe aplastic anemia is a treatment ARTICLE Stem Cell Transplantation EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society

More information

Transplantation for bone marrow failure: current issues

Transplantation for bone marrow failure: current issues BONE MARROW FAILURES Transplantation for bone marrow failure: current issues Régis Peffault de Latour Service d Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris,

More information

Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD

Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de

More information

7/12/2016 TESTING. Objectives. New Directions in Aplastic Anemia: What's on the Horizon? Better way to evaluate clonal evolution?

7/12/2016 TESTING. Objectives. New Directions in Aplastic Anemia: What's on the Horizon? Better way to evaluate clonal evolution? New Directions in Aplastic Anemia: What's on the Horizon? Amy E. DeZern, MD; MHS Assistant Professor Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD Objectives

More information

(EWOG-MDS/SAA) International Meeting on Childhood MDS and SAA 28 30SEPTEMBER2017. ROMA EVENTI FONTANA DI TREVI Piazza della Pilotta - Roma

(EWOG-MDS/SAA) International Meeting on Childhood MDS and SAA 28 30SEPTEMBER2017. ROMA EVENTI FONTANA DI TREVI Piazza della Pilotta - Roma International Meeting on Childhood MDS and SAA (EWOG-MDS/SAA) ROMA EVENTI FONTANA DI TREVI Piazza della Pilotta - Roma 28 30SEPTEMBER2017 President of the meeting: Prof. Franco Locatelli Scientific committee:

More information

Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO!

Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO! Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO! Phillip Scheinberg, MD Head, Clinical Hematology Hospital A Beneficência Portuguesa de Sao Paulo

More information

Clinical significance of acquired somatic mutations in aplastic anaemia

Clinical significance of acquired somatic mutations in aplastic anaemia Int J Hematol (2016) 104:159 167 DOI 10.1007/s12185-016-1972-8 PROGRESS IN HEMATOLOGY Recent advance in the diagnosis and treatment of bone marrow failure syndromes Clinical significance of acquired somatic

More information

Aplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood

Aplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood

More information

Aplastic Anemia: Fill Er Up! But With What? Speaker s Disclosure Statement. Objectives. Aplastic Anemia: Fill Er Up? But With What?

Aplastic Anemia: Fill Er Up! But With What? Speaker s Disclosure Statement. Objectives. Aplastic Anemia: Fill Er Up? But With What? Fill Er Up! But With What? Karyn Brundige, MSN, CPNP Dana-Farber/Boston Children s Cancer and Blood Disorders Center karyn.brundige@childrens.harvard.edu Speaker s Disclosure Statement I have no industry

More information

Educational Sessions The transplant algorithm in lymphoma (1E) P. Dreger M. Gomes da Silva N. Milpied S. Montoto A. Sureda

Educational Sessions The transplant algorithm in lymphoma (1E) P. Dreger M. Gomes da Silva N. Milpied S. Montoto A. Sureda Educational Sessions The transplant algorithm in lymphoma (1E) Chairs: P. Dreger, Germany; M. Gomes da Silva, Portugal o High grade lymphoma: N. Milpied, France o Role of stem cell transplantation in patients

More information

Introduction. Helen Jessop 1. Dominique Farge 2,3,4,5. Riccardo Saccardi 6. Tobias Alexander 7. Montserrat Rovira 8 Basil Sharrack 9.

Introduction. Helen Jessop 1. Dominique Farge 2,3,4,5. Riccardo Saccardi 6. Tobias Alexander 7. Montserrat Rovira 8 Basil Sharrack 9. Bone Marrow Transplantation https://doi.org/10.1038/s41409-019-0430-7 PERSPECTIVE General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune

More information

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017 Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis

More information

research paper Summary

research paper Summary research paper Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant Summary This

More information

Immunosuppressive treatment in acquired aplastic anemia. André Tichelli Hematology, University Hospital Basel

Immunosuppressive treatment in acquired aplastic anemia. André Tichelli Hematology, University Hospital Basel Immunosuppressive treatment in acquired aplastic anemia André Tichelli Hematology, University Hospital Basel Why is immunosuppressive treatment a choice for acquired aplastic anemia? Hematopoietic stem

More information

The function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018

The function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018 The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry

More information

Evidence from bone marrow transplantation

Evidence from bone marrow transplantation Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University

More information

AUTOLOGOUS STEM CELL TRANSPLANTATION for AUTOIMMUNE DISEASES? YES

AUTOLOGOUS STEM CELL TRANSPLANTATION for AUTOIMMUNE DISEASES? YES AUTOLOGOUS STEM CELL TRANSPLANTATION for AUTOIMMUNE DISEASES? YES Pr Dominique Farge, Hôpital St Louis, Paris 7 Denis Diderot University, France, ADWP EBMT Chair The European Group for Blood and Marrow

More information

Aplastic Anemia: Understanding your Disease and Treatment Options

Aplastic Anemia: Understanding your Disease and Treatment Options Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant

More information

Aplastic anemia: therapeutic updates in immunosuppression and transplantation

Aplastic anemia: therapeutic updates in immunosuppression and transplantation IMMUNE DYSREGULATION Aplastic anemia: therapeutic updates in immunosuppression and transplantation Phillip Scheinberg 1 1 Hematology Branch, National Heart, Lung and Blood Institute, National Institutes

More information

Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment

Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment 7/23/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Danielle Townsley, MD, MSc Hematology Branch National, Heart, Lung and Blood Institute National Institutes

More information

Hematopoietic Cell Transplantation for Autoimmune Diseases

Hematopoietic Cell Transplantation for Autoimmune Diseases Medical Policy Manual Transplant, Policy No. 45.32 Hematopoietic Cell Transplantation for Autoimmune Diseases Next Review: April 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT REMINDER

More information

Target audience. Chair. Xxx Xxx

Target audience. Chair. Xxx Xxx STUDENTS FOR FREE EXCEMED WORKSHOP The immunomodulatory role of therapeutic plasma exchange in neuromuscular and PNS diseases: a practical approach & new knowledge London, UK - 19 May 2018 The immunomodulatory

More information

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD. Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific

More information

Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment

Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment 4/18/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Bogdan Dumitriu, MD Hematology Branch National, Heart, Lung and Blood Institute National Institutes of Health

More information

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 09, 2018 Report Length: 7 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 09, 2018 Report Length: 7 Pages CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Eltrombopag for the treatment of Aplastic Anemia: A Review of Clinical and Cost-Effectiveness Service Line: Rapid Response Service Version:

More information

Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options

Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases

More information

Management of acquired aplastic anemia in children

Management of acquired aplastic anemia in children Management of acquired aplastic anemia in children Korthof, E. T.; Békássy, Albert; Hussein, A. A. Published in: Bone Marrow Transplantation DOI: 10.1038/bmt.2012.235 Published: 2013-01-01 Link to publication

More information

ARTICLES. Introduction

ARTICLES. Introduction ARTICLES Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic

More information

Clonality & Aplastic anemia / PNH

Clonality & Aplastic anemia / PNH Clonality & Aplastic anemia / PNH What is in a word W Shakespear : Hamlet Prof G SOCIE, MD, PhD Head Division of Hematology / Immunology / Oncology French reference Center Aplastic Anemia & PNH Hospital

More information

Comment devenir CCA en un WE? HPN aplasie médullaire

Comment devenir CCA en un WE? HPN aplasie médullaire Comment devenir CCA en un WE? HPN aplasie médullaire Régis Peffault de Latour, MD, PhD Saint Louis Hospital, Paris; regis.peffaultdelatour@sls.aphp.fr AIH 27 Septembre 2014 Paroxysmal Nocturnal Hemoglobinuria

More information

Sixth International Bone Marrow Failure Disease Scientific Symposium. Collaborating to Transform Treatment and Improve Outcomes. Summary for Patients

Sixth International Bone Marrow Failure Disease Scientific Symposium. Collaborating to Transform Treatment and Improve Outcomes. Summary for Patients Sixth International Bone Marrow Failure Disease Scientific Symposium Collaborating to Transform Treatment and Improve Outcomes Summary for Patients AAMDSIF would like to thank the corporations whose generous

More information

Stem-Cell Transplantation for Autoimmune Diseases/Miscellaneous Conditions

Stem-Cell Transplantation for Autoimmune Diseases/Miscellaneous Conditions Medical Coverage Policy Effective Date...09/15/2017 Next Review Date...09/15/2018 Coverage Policy Number... 0357 Stem-Cell Transplantation for Autoimmune Diseases/Miscellaneous Conditions Table of Contents

More information

Aplastic Anemia Pathophysiology and Approach to Therapy

Aplastic Anemia Pathophysiology and Approach to Therapy Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes

More information

Bone Marrow Transplantation in Neurological Disease

Bone Marrow Transplantation in Neurological Disease Bone Marrow Transplantation in Neurological Disease Dr. Mark S. Freedman MSc MD FAAN FANA CSPQ FRCPC Professor or Neurology University of Ottawa Sr. Scientist, The Ottawa Hospital Research Institute Ottawa,

More information

18 th EULAR Postgraduate Course

18 th EULAR Postgraduate Course 18 th EULAR Postgraduate Course Belgrade, Serbia 22 25 October 2017 eular.org ORGANISATION AND COMMITTEE Scientific organiser Professor, Serbia Chairperson EULAR standing Committee on Education and Training

More information

Target audience. Chair. Xxx Xxx

Target audience. Chair. Xxx Xxx EXCEMED WORKSHOP The immunomodulatory role of therapeutic plasma exchange in neuromuscular and PNS diseases: a practical approach & new knowledge London, UK - 19 May 2018 The immunomodulatory role of therapeutic

More information

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia The new england journal of medicine Original Article Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Danielle M. Townsley, M.D., Phillip Scheinberg, M.D., Thomas Winkler, M.D., Ronan

More information

Nontransplant therapy for bone marrow failure

Nontransplant therapy for bone marrow failure Nontransplant therapy for bone marrow failure Danielle M. Townsley and Thomas Winkler BONE MARROW FAILURES Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD Nontransplant therapeutic

More information

Hematopoietic Stem Cell Transplantation for Autoimmune Diseases

Hematopoietic Stem Cell Transplantation for Autoimmune Diseases Protocol Hematopoietic Stem Cell Transplantation for Autoimmune Diseases (80125) Medical Benefit Effective Date: 04/01/14 Next Review Date: 11/17 Preauthorization Yes Review Dates: 04/07, 05/08, 01/10,

More information

Immunotherapies for aplastic anemia

Immunotherapies for aplastic anemia Workshop on Hematology and Bone Marrow Transplant May 11 12, 2018, São Paulo Immunotherapies for aplastic anemia Diego Villa Clé, MD, PhD Attending Physician Hospital das Clínicas Faculdade de Medicina

More information

a SAA-WP trial RACE study Sponsor Protocol Number: EudraCT TrialNumber: Coordinating Investigators:

a SAA-WP trial RACE study Sponsor Protocol Number: EudraCT TrialNumber: Coordinating Investigators: A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hatg) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients. RACE

More information

Transplants and T Cells: New Solutions for Old Problems?

Transplants and T Cells: New Solutions for Old Problems? Transplants and T Cells: New Solutions for Old Problems? Tuesday 25 th September 2018 Crowne Plaza Hotel City Centre Wollaton Street, Nottingham NG1 5RH Welcome Welcome to Nottingham! The field of immunotherapy

More information

Severe Chronic Neutropenia

Severe Chronic Neutropenia Haematopoietic Stem Cell Transplantation Severe Chronic Neutropenia F. Fioredda Unit of Haematology Giannina Gaslini Children s Hospital No disclosures Severe Chronic Neutropenia Persistence above 6 months

More information

How I treat acquired aplastic anemia

How I treat acquired aplastic anemia How I treat acquired aplastic anemia Phillip Scheinberg and Neal S. Young Blood Volume 120(6):1185-1196 August 9, 2012 2012 by American Society of Hematology Symptoms, Signs, and Lab Findings Bruising,

More information

International Meeting dedicated to the memory of Raisa Gorbacheva. HEMOPOIETIC STEM CELLS TRANSPLANTATION Saint-Petersburg, September 21-22, 2007

International Meeting dedicated to the memory of Raisa Gorbacheva. HEMOPOIETIC STEM CELLS TRANSPLANTATION Saint-Petersburg, September 21-22, 2007 International Meeting dedicated to the memory of Raisa Gorbacheva HEMOPOIETIC STEM CELLS TRANSPLANTATION Saint-Petersburg, September 21-22, 2007 Preliminary program September 21 Friday 8.00-8.30 - registration

More information

Hematopoietic Stem Cell Transfusion for Autoimmune diseases Clínica Ruiz

Hematopoietic Stem Cell Transfusion for Autoimmune diseases Clínica Ruiz Hematopoietic Stem Cell Transfusion for Autoimmune diseases Clínica Ruiz Background: Since 1993, scientists from the Centro de Hematología y Medicina Interna de Puebla (CHMI) have engaged in practicing

More information

4nd Patient and Family Day

4nd Patient and Family Day 4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,

More information

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,

More information

ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman.

ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman. ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman. to change at any time www.arlar.org info@arlar.org #ArLAR2018 Thursday, 22

More information

4/3/2013. First Risk Stratification: Rule out Inherited Marrow Failure Disease

4/3/2013. First Risk Stratification: Rule out Inherited Marrow Failure Disease Improved Outcome Following Unrelated Donor Allografts: When Should BMT Be Considered for Adults and Children with Severe Aplastic Anemia? Michael Pulsipher, MD Professor Of Pediatrics/Internal Medicine

More information

3 rd EBMT International Transplant Course

3 rd EBMT International Transplant Course 3 rd EBMT International Transplant Course 07 th 9 th September 2018, University of Barcelona, Faculty of Medicine Carrer de Casanova 143, 08036 Barcelona, Spain #EBMTITC18 EBMT International WELCOME It

More information

Current Status of Haploidentical Hematopoietic Stem Cell Transplantation

Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT

More information

Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial

Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial Blood First Edition Paper, prepublished online June 28, 2002; DOI 10.1182/blood-2002-02-0494 Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy):

More information

18 th EULAR Postgraduate Course

18 th EULAR Postgraduate Course 18 th EULAR Postgraduate Course Belgrade, Serbia 22 25 October 2017 eular.org ORGANISATION AND COMMITTEE Scientific organiser Professor, Serbia Chairperson EULAR standing Committee on Education and Training

More information

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals

More information

Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura

Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor

More information

Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra

Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure

More information

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment

More information

Articles and Brief Reports

Articles and Brief Reports Articles and Brief Reports Stem Cell Transplantation Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin

More information

Version 1.11 of 20/07/2018

Version 1.11 of 20/07/2018 Version 1.11 of 20/07/2018 NICE JANUARY 17-19, 2019 6 th International Workshop on Lung Health New approaches to respiratory diseases PRESIDENTS: F. BLASI, G.W. CANONICA CHAIRMEN: S. CENTANNI, J.C. VIRCHOW,

More information

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs

More information

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Marcelo C. Pasquini, MD, MSc HVD05_1.ppt Outline Review of autoimmune diseases (AID). Role of transplantation for AID Data collection:

More information

Monday, March 27th 16:30-18:00. Oral 6: Autoimmune diseases and solid tumors

Monday, March 27th 16:30-18:00. Oral 6: Autoimmune diseases and solid tumors Monday, March 27th 16:30-18:00 Oral 6: Autoimmune diseases and solid tumors Outcome of autologous non-myeloablative hematopoietic stem cell transplantation in patients with refractory Chronic Inflammatory

More information

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives

More information

Annual Conference of the Canadian Blood and Marrow Transplant Group. June 11 to 14, 2014 The Westin Nova Scotian 1181 Hollis Street Halifax, NS

Annual Conference of the Canadian Blood and Marrow Transplant Group. June 11 to 14, 2014 The Westin Nova Scotian 1181 Hollis Street Halifax, NS Annual Conference of the Canadian Blood Preliminary Program In conjunction with the Canadian National, Canadian Apheresis Group, Society, and Vector CBMTG Head Office Malachite Management Inc 375 West

More information

How I manage aplastic anaemia in children

How I manage aplastic anaemia in children state of the art review How I manage aplastic anaemia in children Sujith Samarasinghe 1 and David K. H. Webb 2 1 Paediatric Haematopoietic Stem Cell Transplant Unit, Department of Adolescent and Paediatric

More information

9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History

9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School

More information

Clinical Policy Title: Stem cell transplants for autoimmune disease

Clinical Policy Title: Stem cell transplants for autoimmune disease Clinical Policy Title: Stem cell transplants for autoimmune disease Clinical Policy Number: 18.03.02 Effective Date: April 1, 2016 Initial Review Date: June 16, 2013 Most Recent Review Date: January 18,

More information

IVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen

IVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,

More information

REPORT. KEY WORDS: Severe aplastic anemia, Blood and marrow transplantation, Immunosuppressive therapy, Telomeres

REPORT. KEY WORDS: Severe aplastic anemia, Blood and marrow transplantation, Immunosuppressive therapy, Telomeres REPORT Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_autoimmune_diseases

More information

Management of acquired aplastic anemia in children

Management of acquired aplastic anemia in children Bone Marrow Transplantation (2013) 48, 191 195 & 2013 Macmillan Publishers Limited All rights reserved 0268-3369/13 www.nature.com/bmt REVIEW Management of acquired aplastic anemia in children ET Korthof

More information

Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin

Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin Published Ahead of Print on July 13, 2017, as doi:10.3324/haematol.2017.171215. Copyright 2017 Ferrata Storti Foundation. Long-term risk of cancer development in adult patients with idiopathic aplastic

More information

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009 (2010) 45, 219 234 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 $32.00 www.nature.com/bmt SPECIAL REPORT Allogeneic and autologous transplantation for haematological diseases, solid

More information

Aplastic Anemia: Management of Adult Patients

Aplastic Anemia: Management of Adult Patients Aplastic Anemia: Management of Adult Patients Jaroslaw P. Maciejewski and Antonio M. Risitano The primary therapeutic approach to acquired aplastic anemia (AA) in older adults differs from the primary

More information

Making Therapeutic Decisions in Adults with Aplastic Anemia

Making Therapeutic Decisions in Adults with Aplastic Anemia Making Therapeutic Decisions in Adults with Aplastic Anemia Judith Marsh The management of adults presenting with aplastic anemia (AA) requires careful exclusion of other causes of bone marrow failure.

More information

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 CIC: HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?:

More information

Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience

Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience 36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC

More information

BREAKS NETWORKING EVENTS PARALLEL SESSIONS INDUSTRY SUPPORTED SESSIONS Academy of Autoimmunity SYMPOSIUM

BREAKS NETWORKING EVENTS PARALLEL SESSIONS INDUSTRY SUPPORTED SESSIONS Academy of Autoimmunity SYMPOSIUM PLENARY SESSIONS BREAKS NETWORKING EVENTS PARALLEL SESSIONS INDUSTRY SUPPORTED SESSIONS SYMPOSIUM Monday, 14 May 2018 13:00-15:30 15:30 16:00 COFFEE BREAK 16:00-17:30 Tuesday, 15 May 2018 08:00-08:30 08:30-10:30

More information

Int J Clin Exp Med 2015;8(9): /ISSN: /IJCEM

Int J Clin Exp Med 2015;8(9): /ISSN: /IJCEM Int J Clin Exp Med 2015;8(9):16334-16339 www.ijcem.com /ISSN:1940-5901/IJCEM0011065 Original Article Not all anti-t lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly

More information

Clinical Policy Title: Stem cell transplants for autoimmune disease

Clinical Policy Title: Stem cell transplants for autoimmune disease Clinical Policy Title: Stem cell transplants for autoimmune disease Clinical Policy Number: 18.03.02 Effective Date: April 1, 2016 Initial Review Date: June 16, 2013 Most Recent Review Date: January 11,

More information

First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated

First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated Received: 30 January 2018 Revised: 24 February 2018 Accepted: 26 February 2018 DOI: 10.1002/ajh.25081 RESEARCH ARTICLE First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome

More information

PNH from the perspective of Paediatric Haematologists

PNH from the perspective of Paediatric Haematologists EBMT Severe Aplastic Anaemia and Infectious Diseases Working Parties Bruno Rotoli Memorial Educational Course 29 Sept 1 Oct 2014 PNH from the perspective of Paediatric Haematologists Fabio Timeus, MD PhD

More information

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?:

More information

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?:

More information

Fungal infections. Ematologia. Corrado Girmenia. Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy

Fungal infections. Ematologia. Corrado Girmenia. Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy Fungal infections Corrado Girmenia Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy Ematologia Epidemiology Diagnostic approach Prevention strategies Monitoring of IFDs in

More information

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal

More information

Andrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?

Andrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG? What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our

More information

STEP BY STEP. Aplastic Anaemia

STEP BY STEP. Aplastic Anaemia STEP BY STEP Aplastic Anaemia Introduction Being diagnosed with aplastic anaemia (AA) can be a shock, particularly when you may have never heard of it. If you have questions about AA, what causes it, who

More information

Aplastic Anemia: Current Thinking

Aplastic Anemia: Current Thinking Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?

More information